Cargando…

Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer

Background: Recent studies confirmed that immunotherapy showed prominent efficacy in non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells are resistant to anticancer treatment. The purpose of the study was to analyze the correlation of cancer stem cells/cancer initiating cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhaoqin, Yu, Haining, Zhang, Jianbo, Jing, Haiyan, Zhu, Wanqi, Li, Xiaolin, Kong, Lingling, Xing, Ligang, Yu, Jinming, Meng, Xiangjiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665035/ https://www.ncbi.nlm.nih.gov/pubmed/29158791 http://dx.doi.org/10.7150/jca.20172

Ejemplares similares

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus
por: Zhao, Kaikai, et al.
Publicado: (2021)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review
por: Jiang, Liyang, et al.
Publicado: (2020)

Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature
por: Chen, Yu, et al.
Publicado: (2020)

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
por: Ma, Lin, et al.
Publicado: (2021)

Use of Chemoradiotherapy as a Treatment Option for Patients with Limited-Stage Primary Small Cell Carcinoma of the Esophagus
por: Zhao, Kaikai, et al.
Publicado: (2021)

Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study
por: Chen, Yu, et al.
Publicado: (2022)

Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer
por: Wang, Nannan, et al.
Publicado: (2019)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy
por: Zhu, Wanqi, et al.
Publicado: (2016)

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
por: Chen, Yu, et al.
Publicado: (2020)

The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma
por: Dong, Xinzhe, et al.
Publicado: (2017)

Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
por: Meng, Xiangjiao, et al.
Publicado: (2014)

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study
por: Zhu, Wanqi, et al.
Publicado: (2021)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
por: Chen, Yu, et al.
Publicado: (2020)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
por: Liu, Jing, et al.
Publicado: (2016)

Markers of small cell lung cancer
por: Taneja, Tarvinder K, et al.
Publicado: (2004)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Chen, Yu, et al.
Publicado: (2021)

Clinical application of biological markers for treatments of resectable non-small-cell lung cancers
por: Huang, C, et al.
Publicado: (2005)

The prognostic value of TCF1+CD8+T in primary small cell carcinoma of the esophagus
por: Ma, Lin, et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial
por: Xie, Jingjing, et al.
Publicado: (2023)

Stem Cells, Colorectal Cancer and Cancer Stem Cell Markers Correlations
por: CHERCIU, IRINA, et al.
Publicado: (2014)

Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer
por: Wang, Yao, et al.
Publicado: (2022)

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis
por: Zhu, Ying, et al.
Publicado: (2019)

Prognostic Value of (18)F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis
por: Liu, Jing, et al.
Publicado: (2016)

Lack of correlation of stem cell markers in breast cancer stem cells
por: Liu, Y, et al.
Publicado: (2014)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
por: Usó, Marta, et al.
Publicado: (2016)

The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer
por: Jin, Feng, et al.
Publicado: (2016)

Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer
por: Zeng, Haiyan, et al.
Publicado: (2017)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Lack of correlation between markers of breast cancer initiating cells
por: Liu, Y, et al.
Publicado: (2010)

A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review
por: Jin, Feng, et al.
Publicado: (2015)

The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Meng, Xiangjiao, et al.
Publicado: (2014)

Novel image markers for non-small cell lung cancer classification and survival prediction
por: Wang, Hongyuan, et al.
Publicado: (2014)

Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
por: Shangguan, Jian, et al.
Publicado: (2023)

Estimating Survival in Patients with Non-Small-Cell Lung Cancer and Brain Metastases: A Verification of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
por: Li, Ji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bje36h2doo6moficubivt5i647